首页> 美国卫生研究院文献>Journal of Clinical Medicine >Initial Glaucoma Medication in the Hypertensive Phase Following Ahmed Valve Implantation: A Comparison of Results Achieved Using Aqueous Suppressants and Prostaglandin Analogs
【2h】

Initial Glaucoma Medication in the Hypertensive Phase Following Ahmed Valve Implantation: A Comparison of Results Achieved Using Aqueous Suppressants and Prostaglandin Analogs

机译:Ahmed瓣膜植入术后高血压期青光眼的初始药物治疗:使用水性抑制剂和前列腺素类似物获得的结果比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: To compare the effects of aqueous suppressants (AS) and prostaglandin (PG) analogs during the hypertensive phase on intraocular pressure (IOP) and surgical outcomes. Methods: In this retrospective, observational study, 66 eyes (66 patients) with Ahmed glaucoma valve (AGV) implantation were included. As evaluation items, IOP changes, number of postoperative medications, the surgical success rate, and postoperative complications were examined. Complete success was defined as IOP between 6 and 21 mmHg without medications, while qualified success was with a maximum of four medications. Results: The short-term IOP reduction following initial medication was 9.3 mmHg for AS and 4.4 mmHg for PG analogs ( = 0.016). More postoperative medications were used in PG than in AS from postoperative 3 months to 3 years (all < 0.05). The qualified success rate with the initial medication was higher in AS than in PG (67.5% vs. 42.3% at 1 year, 80.6% vs. 37.5% at 2 years, 80.0% vs. 35.0% at 3 years, all < 0.05). Conclusions: Association between AS used as the first medications during the hypertensive phase and better IOP control and a higher success rate was observed. The type of the initial glaucoma medication after AGV implantation could affect short- and long-term surgical outcomes.
机译:背景:为了比较高血压期水抑制剂(AS)和前列腺素(PG)类似物对眼内压(IOP)和手术结局的影响。方法:这项回顾性观察研究纳入了66眼(66例患者)的艾哈迈德青光眼瓣膜(AGV)植入术。作为评估项目,检查了眼压变化,术后用药数量,手术成功率和术后并发症。完全成功的定义是在不使用药物的情况下,眼压介于6至21 mmHg之间,而合格的成功则是最多使用四种药物。结果:初始用药后短期眼压降低对于AS为9.3 mmHg,对于PG类似物为4.4 mmHg(= 0.016)。从术后3个月到3年,PG中使用的术后药物比AS中使用的药物更多(所有<0.05)。 AS的初始药物合格成功率高于PG(1年为67.5%比42.3%,2年为80.6%比37.5%,3年为80.0%比35.0%,均<0.05) 。结论:在高血压期AS作为首选药物与更好的IOP控制之间存在关联,并观察到较高的成功率。 AGV植入后初始青光眼药物的类型可能会影响短期和长期手术结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号